Ernexa Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Ernexa Therapeutics Inc. (ERNA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $7.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2017-03-09
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2015-06-30 was $3.00K, a 90.63% decline year-over-year.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2015-03-31 was $4.00K, a 42.86% decline year-over-year.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2016 was $7.00K, a 0.00% change from fiscal 2015.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2015 was $7.00K, a 91.14% decline from fiscal 2014.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2014 was $79.00K, a 1216.67% increase from fiscal 2013.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2013 was $6.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2016-12-31 | $7.00K 10-K · filed 2017-03-09 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $0.00 derived: sum of 2 quarters · filed 2016-03-15 | $3.00K derived: sum of 3 quarters · filed 2016-03-15 | $7.00K 10-K · filed 2016-03-15 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $3.00K derived: sum of 2 quarters · filed 2015-11-09 | $7.00K 10-Q · filed 2015-11-09 | $26.00K derived: sum of 4 quarters · filed 2015-11-09 |
| 2015-06-30 | $3.00K 10-Q · filed 2015-08-10 | $7.00K 10-Q · filed 2015-08-10 | $26.00K derived: sum of 3 quarters · filed 2015-08-10 | $46.00K derived: sum of 4 quarters · filed 2015-11-09 |
| 2015-03-31 | $4.00K 10-Q · filed 2015-05-08 | $23.00K derived: sum of 2 quarters · filed 2015-05-08 | $43.00K derived: sum of 3 quarters · filed 2015-11-09 | $75.00K derived: sum of 4 quarters · filed 2015-11-09 |
| 2014-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $39.00K derived: sum of 2 quarters · filed 2015-11-09 | $71.00K derived: sum of 3 quarters · filed 2015-11-09 | $79.00K 10-K · filed 2015-03-27 |
| 2014-09-30 | $20.00K 10-Q · filed 2015-11-09 | $52.00K derived: sum of 2 quarters · filed 2015-11-09 | $60.00K 10-Q · filed 2015-11-09 | $61.00K derived: sum of 4 quarters · filed 2015-11-09 |
| 2014-06-30 | $32.00K 10-Q · filed 2015-08-10 | $39.00K 10-Q · filed 2015-08-10 | $41.00K derived: sum of 3 quarters · filed 2015-08-10 | $43.00K derived: sum of 4 quarters · filed 2015-08-10 |
| 2014-03-31 | $7.00K 10-Q · filed 2015-05-08 | $9.00K derived: sum of 2 quarters · filed 2015-05-08 | $11.00K derived: sum of 3 quarters · filed 2015-05-08 | |
| 2013-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-31 | $4.00K derived: sum of 2 quarters · filed 2014-11-07 | $6.00K 10-K · filed 2014-03-31 | |
| 2013-09-30 | $2.00K 10-Q · filed 2014-11-07 | $4.00K 10-Q · filed 2014-11-07 | ||
| 2013-06-30 | $2.00K 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |